Gujarat Kidney & Super Speciality
CLOSEDIPO Date: 22 Dec - 24 Dec 2025
Listing Date: 30 Dec 2025
Price Range
Rs.108 - Rs.114
Issue Size
251 Cr
Min Investment
₹13,824
Lot Size
128 Shares
Schedule of Gujarat Kidney & Super Speciality
Issue open date
22 Dec 2025
Issue close date
24 Dec 2025
UPI mandate deadline
24 Dec 2025 (5 PM)
Allotment finalization
26 Dec 2025
Share credit
29 Dec 2025
Listing date
30 Dec 2025
Mandate end date
9 Jan 2026
Issue size
| Funds Raised in the IPO | Amount |
|---|---|
| Overall | 251 Cr |
| Fresh Issue | 250.8 Cr |
| Offer for Sale | 0 Cr |
Allotment DetailsNew
| Allotment Timeline | Details |
|---|---|
| Allotment Date | 26 Dec 2025 |
| Allotment Link | {Link} |
Grey Market PremiumNew
Grey Market Premium (GMP) is the premium at which the shares are traded in the grey market. It gives a fair idea about the listing price of the IPO shares. The GMP can be positive or negative based on the demand and supply of the shares in the grey market.
| Date | Ipo Price | GMP | Estimated Listing Price |
|---|
Performance Gujarat Kidney & Super Speciality
| Issue Price | Listing Gain | Current Market Price | P/L |
|---|---|---|---|
| Rs.108 - Rs.114 | ₹ 233 (5.26%) | ₹ 101.8 | -10.70% |
About Gujarat Kidney & Super Speciality
Gujarat Kidney and Super Speciality operates a regional chain of mid-sized multispeciality hospitals in central Gujarat, focusing on secondary and tertiary care. The company manages seven hospitals and four in-house pharmacies across Vadodara, Godhra, Bharuch, Borsad, and Anand, with a total bed capacity of 490 beds, an approved capacity of 445 beds, and an operational capacity of 340 beds. Its services include secondary surgical treatments, super speciality surgical services, integrated diagnostic facilities, and pharmacy operations within its hospitals. The network provides both general and specialised care, and supports patients covered under government schemes, public sector undertakings, and private companies. The company operates through a consolidated structure with professional management teams at each hospital and employs medical and administrative staff across its facilities.
| Founded in | 2019 |
| Managing director | Dr. Pragnesh Yashwantsinh Bharpoda |
| Parent organization |
Financial Overview
Strengths
- Strong capabilities in renal sciences with established urology subspecialties.
- Strategically located, right-sized hospitals providing efficient capital returns.
- Proven ability to attract, train, and retain skilled medical professionals.
- Continuous investment in infrastructure and clinical processes supporting affordable care.
- Strong operational and financial performance with a track record of growth.
Risks
- The company has acquired several hospitals from promoters and may continue such related-party acquisitions.
- Acquisitions and integrations involve operational, financial, and regulatory risks.
- Rapid expansion across multiple hospitals increases management and operational complexity.
- Dependence on promoter-led expertise poses concentration and continuity risks.
- Hospitals lacking certain departments may limit service breadth.
Subscription Figures
| Category | Subscription (No. of times) |
|---|---|
| Qualified Institutional Buyers (QIBs) | 1.06 |
| Non-Institutional Investors (NIIs) | 5.68 |
| Retail Individual Investors (RIIs) | 18.29 |
| Employee | N/A |
| Total | 5.08 |